Compare · DXCM vs TMCI
DXCM vs TMCI
Side-by-side comparison of DexCom Inc. (DXCM) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 107.6x TMCI ($312.8M).
- DXCM has been more active in the news (9 items in the past 4 weeks vs 8 for TMCI).
- DXCM has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- DexCom Inc.
- Treace Medical Concepts Inc.
- Price
- $89.16-2.09%
- $4.79+9.60%
- Market cap
- $33.65B
- $312.8M
- 1M return
- +21.53%
- -
- 1Y return
- +17.08%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 19
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest TMCI
- Chief Executive Officer Treace John T. bought $246,654 worth of shares (55,944 units at $4.41), increasing direct ownership by 0.76% to 7,404,383 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.
- Chief Innovation Officer Scanlan Sean F. covered exercise/tax liability with 9,814 shares, decreasing direct ownership by 1% to 679,863 units (SEC Form 4)
- Chief Financial Officer Hair Mark covered exercise/tax liability with 37,102 shares, decreasing direct ownership by 4% to 914,900 units (SEC Form 4)
- Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 16,253 shares, decreasing direct ownership by 2% to 778,683 units (SEC Form 4)
- SEC Form 10-Q filed by Treace Medical Concepts Inc.
- Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Treace Medical Concepts Reports Second Quarter 2026 Financial Results
- Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
- Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System